BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/30/2024 6:47:30 AM | Browse: 124 | Download: 478
 |
Received |
|
2024-08-21 05:55 |
|
Peer-Review Started |
|
2024-07-19 09:03 |
|
First Decision by Editorial Office Director |
|
2024-11-10 03:24 |
|
Return for Revision |
|
2024-11-10 03:24 |
|
Revised |
|
2024-11-13 11:12 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-11-20 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-11-20 07:08 |
|
Articles in Press |
|
2024-11-20 07:08 |
|
Edit the Manuscript by Language Editor |
|
2024-12-02 01:13 |
|
Typeset the Manuscript |
|
2024-12-04 00:05 |
|
Publish the Manuscript Online |
|
2024-12-30 06:47 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Elafibranor, a dual PPARα and PPARδ agonist, reduces alcohol-associated liver disease: Lessons from a mouse model
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Luciano Pirola |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Luciano Pirola, PhD, Carmen Laboratory, INSERM Unit 1060-Lyon 1 University, CENS ELI-2D Building, 165 Chemin du Grand Revoyet, Pierre Benite 69310, France. luciano.pirola@univ-lyon1.fr |
| Key Words |
PPAR nuclear receptors; Elafibranor; Steatotic liver disease; Alcohol associated liver disease; Liver fibrosis |
| Core Tip |
Metabolic dysfunction-associated steatotic liver disease (SLD) needs novel pharmacological treatments elafibranor, a PPAR agonist, remains a promising molecule against SLD caused by alcohol consumption. Koizumi et al, report, using a mouse model of alcohol-associated liver disease, that hepatic steatosis, liver fibrosis and hepatocyte apoptosis are alleviated by administration of elafibranor. These data support the potential beneficial action of elafibranor, warranting clinical testing. |
| Publish Date |
2024-12-30 06:47 |
| Citation |
Pirola L. Elafibranor, a dual PPARα and PPARδ agonist, reduces alcohol-associated liver disease: Lessons from a mouse model. World J Gastroenterol 2025; 31(4): 99312 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i4/99312.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i4.99312 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
